Concomitant Presence of EGFR and ALK Fusion Gene Mutation in Adenocarcinoma of Lung: A Case Report and Review of the Literature.
J Pharm Pract
; 31(2): 244-248, 2018 Apr.
Article
in En
| MEDLINE
| ID: mdl-28438075
ABSTRACT
Empirical evidence has long suggested that oncogenic driver mutations in non-small-cell lung cancer are mutually independent. However, recent studies reported in pertinent literature reveal that concomitant epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangement can occur in a subset of patients with NSCLC. In order to shed further light on this issue, we report a case of adenocarcinoma of lung harboring both EGFR mutation in exon 21 (L861Q) and ALK rearrangement. This allows us to speculate on likely molecular mechanisms underlying this uncommon phenomenon, while also offering some practical guidelines on the therapeutic options that could benefit patients diagnosed with this dual-positive tumor.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Adenocarcinoma
/
Receptor Protein-Tyrosine Kinases
/
ErbB Receptors
/
Lung Neoplasms
/
Mutation
Type of study:
Guideline
Limits:
Aged
/
Humans
/
Male
Language:
En
Journal:
J Pharm Pract
Journal subject:
FARMACIA
Year:
2018
Document type:
Article
Affiliation country: